Introduction
The meniscus has important functions in load bearing and shock absorption, and in the stability of the knee joint, 1 appearing to be particularly susceptible to injury. Meniscal tears that are associated with pain, locking, and effusion can be disabling and predispose the adjacent cartilage to osteoarthritis. 2 Longitudinal tears in the peripheral, vascularized portion of the meniscus (10-30% of the total structure) can be sutured, but lesions in the central avascular region do not heal. 3, 4 Reconstruction of a torn meniscus in this area has not been achieved to date, 4 and the long-term progression of allografts remains uncertain. 5, 6 The meniscus is made of fibrocartilaginous elements constituting an extracellular matrix mainly composed of collagen (predominantly type-I collagen, but also type-II, type-III, and type-V collagen), with smaller quantities of proteoglycans synthesized by the resident cells (meniscal fibrochondrocytes). Alterations in the cellularity and constitution in injured menisci have been frequently noted, 5, [7] [8] [9] [10] [11] particularly in older patients 11 and cell death by apoptosis has been shown in experimental models in vivo. 12, 13 Repopulation of sites of injury might, thus, be favorable to promote the healing of meniscal lesions. 14, 15 Delivery of therapeutic genes in the meniscus is an attractive approach to enhance meniscal repair. 16, 17 Candidate factors that stimulate the cellular activities of meniscal fibrochondrocytes include the insulin-like growth factors I and II, 18 fibroblast growth factor 2 (FGF-2), [18] [19] [20] platelet-derived growth factor, 19, [21] [22] [23] transforming growth factor beta, [23] [24] [25] [26] [27] hepatocyte growth factor, 22 and the bone morphogenic proteins 2 and 7. 22, 23 Although several studies have been performed to evaluate the efficacy of nonviral and viral vectors to deliver reporter genes in meniscal cells in vitro, [28] [29] [30] [31] [32] [33] [34] in situ, 30, 35 and in vivo, 30, 34, 36 little is known about the value of applying therapeutic gene sequences in the injured meniscus. Administration of a retroviral vector carrying the sequence for transforming growth factor beta was shown to stimulate the synthesis of extracellular matrix in meniscal fibrochondrocytes 31 and delivery of hepatocyte growth factor through adenoviral vector transduction was reported to promote cell proliferation in vitro and the formation of a vascularized fibrocartilage in an experimental model system; 33 yet it remains to be seen if such gene-based treatments might be capable of enhancing the repair of meniscal lesions. Most remarkably, Steinert et al. 37 showed the benefits of implanting meniscal cells modified by adenoviruses to overexpress transforming growth factor beta1 in artificially created meniscal tears based on the use of biomatrices. With such an indirect approach, the authors observed the formation of a repair tissue in the avascular zone of the treated defects with increased cellularity and matrix contents. Gene transfer procedures based on the use of vectors derived from the adeno-associated virus (AAV) might offer more potent treatments, as recombinant AAV (rAAV) can directly transduce meniscal cells in situ with high efficiencies, 33 avoiding the need to manipulate the cells ex vivo before reinjecting them in sites of injury. rAAV display several other advantages, as they are small nonpathogenic, replication-defective human vectors, allowing for an enhanced diffusion to their targets in situ. 38 When generating rAAV, all the viral protein coding sequences can be removed, making them less immunogenic than the classical adenoviral vectors. Besides, rAAV can transfer genes both in nondividing and dividing cells in contrast with retroviral vectors. In addition, expression of rAAV transgenes seems to be driven from highly stable episomes, which can persist for months to years, 39 lowering the risk of insertional mutagenesis. These properties make rAAV a currently favored gene transfer system in clinical trials. 40 In this study, we evaluated the ability of rAAV to deliver a human FGF-2 sequence in human meniscal fibrochondrocytes in vitro, within their natural environment in situ, and in experimentally created human meniscal lesions. Owing to the mitogenic properties of the growth factor, we tested the hypothesis that application of the therapeutic vector modulates the proliferative activities in these systems, in particular in the avascular zone of the meniscus and in areas surrounding the defects. Finally, we investigated the metabolic and reparative activities of meniscal fibrochondrocytes in a damaged environment after treatment by the candidate vector.
Results

Efficient and sustained rAAV-mediated therapeutic gene transfer in human meniscal fibrochondrocytes in vitro
Human primary meniscal fibrochondrocytes were first transduced in monolayer cultures using the candidate rAAV-hFGF-2 vector vis-a-vis reporter, control vectors (rAAV-RFP (red fluorescent protein) or rAAV-lacZ) to test the potentiality of rAAV to promote FGF-2 overexpression in these cells in vitro.
Although a fluorescent signal was noted only in cells in which rAAV-RFP was applied (Figure 1 ), significant FGF-2 expression was observed in rAAV-hFGF-2-transduced cells compared with the control condition, with an increase over the time of evaluation (up to 10 days) (up to 136.4±18.4 pg ml -1 per 24 h, that is 68.2±9.1 pg per 10 4 cells per 24 h; Pp0.029) ( Figure 1 ; Table 1 ). Transduced human primary meniscal fibrochondrocytes were next encapsulated in alginate spheres to examine the capacity of the candidate and reporter vectors to induce expression of the rAAV-delivered transgenes in a three-dimensional environment in vitro. Again, specific fluorescence was seen only in rAAV-RFPtransduced, encapsulated cells (Figure 2 ), whereas significant levels of FGF-2 expression were maintained over time in cells from spheres treated by the candidate rAAV-hFGF-2 vector compared with the control condi- Figure 1 rAAV-mediated gene transfer in monolayer cultures of human meniscal fibrochondrocytes. Cells were transduced with rAAV-RFP, rAAV-lacZ, or rAAV-hFGF-2 (50 ml each vector) and processed to monitor transgene expression 10 days after vector application by analyzing live fluorescence (magnification Â 10; insets: same fields under transmitted light) and FGF-2 immunoreactivity (magnification Â 20; insets: magnification Â 10). The effects of FGF-2 treatment on cell proliferation were also examined by immunochemical labeling after BrdU incorporation (magnification Â 20; insets: magnification Â 10). (Figure 2 ; Table 2 ). Transduction efficiencies were ranging between 53 and 59% in both types of systems (Figures 1 and 2) , consistent with earlier data using rAAV. 34 Treatment by rAAV-hFGF-2 enhances the proliferation and survival of human meniscal fibrochondrocytes in vitro Transduced human meniscal fibrochondrocytes were next processed to monitor the effects of rAAV-mediated FGF-2 overexpression over time on the metabolic activities of the cells in vitro compared with control vector application.
Analyses in transduced monolayer cultures of human primary meniscal fibrochondrocytes revealed a significantly enhanced rate of proliferation in cells treated by rAAV-hFGF-2 (82 ± 2% BrdU-positive cells) compared with the control vector application (10±1% BrdU-positive cells, that is a 8.2-fold increase; Pp0.001) (Figure 1) . Application of rAAV-hFGF-2 to human primary meniscal fibrochondrocytes in a three-dimensional environment led to a significant increase in cell numbers in the treated spheres compared with the control spheres (Pp0.001) (Figure 3a) . Over time, the number of cells decreased in the control spheres (Pp0.001), whereas they increased (P ¼ 0.003) or were maintained (P ¼ 0.247) in the treated spheres. Consistent with this, cell viability in the control spheres was only 38% at the end of the evaluation period, much lower than in the treated spheres (94%) and compared with an initial viability of 91% when they were established. The differences in outcome were, therefore, a combination of increased cell viability and cell division produced by FGF-2. These results were confirmed when analyzing the cell densities on sections from spheres (Figure 3b ), the rate of cell proliferation in the spheres (87±2% BrdU-positive cells in the treated spheres compared with 8 ± 1% in the control spheres, that is a 10.9-fold increase; Pp0.001) (Figure 3c ), and the DNA contents in spheres (a 16.1-fold increase in the treated compared with the control spheres on day 21; Pp0.002) ( Table 2 ). In contrast, there was no significant difference in the type-I, type-II collagen, and proteoglycan contents and type-I collagen immunostaining between the treated and control spheres at any time point of the analysis (PX0.097), with a decrease over time in the type-I collagen and proteoglycan contents (Pp0.029) (Table 2; Figure 3d ). Notably, the type-I collagen contents were always superior to those for type-II collagen and proteoglycans. An analysis of the relative amounts of matrix components to the corresponding DNA contents revealed that treatment by rAAV-hFGF-2 significantly decreased both the type-I collagen/DNA, type-II collagen/DNA, and proteoglycans/DNA contents at any time point of the evaluation compared with rAAV-lacZ (always Pp0.001) ( Table 2 ). 
Metabolic responses of human meniscal fibrochondrocytes to FGF-2 production M Cucchiarini et al
Direct administration of rAAV-hFGF-2 enhances cell proliferation and a-smooth muscle actin expression in human meniscal lesions
Human meniscal explants were next transduced with the constructs to evaluate the ability of rAAV to promote candidate gene expression in situ and to further determine the effects of the FGF-2 treatment on the metabolic and reparative activities of meniscal fibrochondrocytes in a native (intact meniscus) or experimentally modified environment (meniscal lesion) vis-a-vis control vector application. As observed in vitro, a fluorescent signal was noted only in the presence of rAAV-RFP (Figure 4 ), whereas significant levels of FGF-2 expression were maintained over time in rAAV-hFGF-2-transduced intact and injured menisci compared with the control condition (Pp0.029) (Figure 4 ; Tables 3 and 4 ). Specific transgene expression was noted in the peripheral and central parts of the intact explants and in cells juxtaposing and surrounding the lesions, showing transduction efficiencies of 70-75%.
In good agreement with the findings in primary cultures, the cell densities in the peripheral and central parts of the intact menisci were significantly higher in the treated compared with the control menisci at the end of the evaluation period (3.1-fold; always Pp0.001) ( Figure 5 ; Table 3 ). As well, there was a significant augmentation of the rate of cell proliferation in the intact menisci transduced by rAAV-hFGF-2 (88±2% BrdUpositive cells versus 4±1% in the control menisci, that is a 22-fold increase; Pp0.001) ( Figure 5 ). In addition, the DNA contents in the treated intact menisci were 4.1-fold increased on day 15 compared with the control menisci (Pp0.001) ( Table 3) . Particularly important for the development of an effective therapeutic component, injection of the candidate FGF-2 vector within experimentally created meniscal lesions promoted a significant decrease in the amplitude of the defects at the end of the evaluation period both in depth and in width (up to 2.4-fold; Pp0.001), although not in length (P ¼ 0.361), revealing nonetheless a substantial overall effect (5.2-fold; Pp0.001) ( Figure 5 ; Table 4 ). This was accompanied by a significant increase in the cell densities, rates of cell proliferation (85±3% BrdU-positive cells versus 3±1% in the control menisci, that is a 28-fold increase), and DNA contents in the areas surrounding the meniscal tears vis-a-vis the control defects (always Pp0.001) ( Figure 5 ; Table 4 ), although without significant modification of the type-I, type-II collagen, and proteoglycan contents and percents immunostaining between the treated and control menisci, as also noted in the intact menisci (PX0.382) ( Tables 3 and 4) . Again, the type-I collagen contents were superior to those for type-II collagen and proteoglycans and the ratios type-I collagen/DNA, type-II collagen/DNA, and proteoglycan/ DNA (or specific staining/cells) in the rAAV-hFGF-2-transduced menisci were significantly lower than those in the corresponding control menisci (always Pp0.001) (Tables 3 and 4). As reduction of meniscal tears was not associated with significant enhancements of synthesis of the major extracellular matrix components, we investigated the levels of a-smooth muscle actin (a-SMA) expression, a contractile marker, and a determinant of the response of menisci to injury.
9,41,42 Strikingly, there 
Discussion
Gene transfer methods are promising tools to promote the healing of meniscal lesions, in particular those affecting the central part of the tissue that are excluded from vascularization. Owing to the high susceptibility of the meniscus to injuries that slowly predispose the surrounding cartilage to osteoarthritis, the successful approach to treat meniscal defects will most likely necessitate to deliver a therapeutic candidate with high efficiencies and over extended period of times. This might be difficult to achieve when applying recombinant factors that have relatively short pharmacological halflives. Instead, gene delivery with vectors based on the AAV might be particularly well suited to achieve these goals. Sustained and elevated levels of transgene expression have been reported in meniscal fibrochondrocytes after direct administration of reporter rAAV vectors both in vitro and in vivo, with up to 80% of the cells being efficiently targeted. 28, 29, 34, 36 These properties and the fact that cells do not need to be manipulated ex vivo before rAAV application make this class of vectors currently a favored gene transfer system for clinical purposes compared with retroviruses and with the more immunogenic and less efficient adenoviruses. 30, 35 In this study, we confirmed the high permissivity of human meniscal fibrochondrocytes to rAAV transduction in vitro, and we specifically show that these vectors can mediate elevated and prolonged levels of transgene expression in a three-dimensional cell cultivation system and in human meniscal explants, probably because of the ability of these small vectors to penetrate the extracellular matrix in situ. 38, [43] [44] [45] Most importantly, we provide evidence that rAAV transgene expression in situ can be successfully achieved in zones of poor healing capacity and in sites of injury, as noted on experimentally created human meniscal lesions. 
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Among the factors of potential value for the treatment of meniscal lesions, we examined the ability of rAAVmediated FGF-2 overexpression to modulate the proliferative and metabolic activities of human meniscal fibrochondrocytes in a natural environment, with a particular emphasis on experimental conditions reproducing meniscal injuries in sites of poor healing capacity. The present data indicate that sustained and efficient rAAV-mediated FGF-2 secretion promoted cell proliferation and survival in a three-dimensional in vitro culture system and in meniscal explants, consistent with the established mitogenic properties of FGF-2. 18, 19, 46 The absolute concentrations of FGF-2 produced in the explants after transduction by rAAV-hFGF-2 were higher than those achieved in isolated meniscal fibrochondrocytes using similar vector doses, although the cell densities in situ are inferior to those in established monolayer cultures, most likely because of the higher amounts of cells present in the entirely transduced explants. The concentrations of FGF-2 obtained here in vitro were in the range of those measured when applying the same vector to rabbit chondrocytes (about 12 ng per 10 7 cells per 24 h when adding 300 ml rAAV to 10 6 cells, i.e. 6 ml for 2 Â 10 4 cells or eightfold less than here) 47 or when transfecting bovine chondrocytes with an FGF-2-expressing plasmid vector (82 ng per 10 7 cells per 24 h). 48 In these earlier reports, such production levels were sufficient to induce a measurable biological effect in vitro, in particular to significantly stimulate cell proliferation compared with control treatments. The effects documented in situ were noted both in the peripheral zone of the intact meniscus and in the central, avascular part with low intrinsic repair ability as described earlier when applying a recombinant FGF-2 molecule. 18, 19, 46 Most importantly, the proliferative activities of meniscal fibrochondrocytes were also stimulated by the candidate treatment in areas surrounding the experimental meniscal lesions, an effect that was accompanied by a significant decrease in the amplitude of the artificial defects compared with a control gene administration.
As reduction of the lesions treated by rAAV-hFGF-2 was not associated with an enhanced synthesis of the major extracellular matrix components, in good agreement with the properties of the growth factor, 49 we examined the expression profiles of a-SMA, a contractile marker and a determinant of the response of meniscus to injury. 9, 41, 42 Significant increases in a-SMA levels were noted in areas surrounding the treated lesions, as noted earlier, 50 indicative of a particular response of damaged meniscus to FGF-2 treatment. To our best knowledge, this is the first evidence showing the possible benefits of applying a direct gene delivery approach in the injured human meniscus, most particularly in its most susceptible zone.
Yet, complete reconstruction of the lesions was not afforded by the candidate treatment in the conditions used here. This might have occurred at later time points or when applying superior vector doses to yield higher FGF-2 secretion levels, 18, 19, 46 and in which case presumably higher repopulating cell concentrations, 14, 15 but it is more reasonable to think that healing of meniscal defects may necessitate the activation of additional processes. Interestingly, administration of the rAAV-hFGF-2 vector did not significantly enhance the synthesis of major extracellular matrix components in the systems evaluated, consistent with data using recombinant FGF-2 at approximate concentrations 19 and with our earlier observations in articular cartilage. 45, 47 Instead, treatment by the FGF-2 vector led to a significant reduction in the Metabolic responses of human meniscal fibrochondrocytes to FGF-2 production M Cucchiarini et al matrix/DNA contents. This is in good agreement with the reported negative effects of FGF-2 on the production and accumulation of matrix molecules, in particular in the cartilage. 49, 51 Relevant to the present approach, increased production of proteoglycan and type-II collagen has been documented in aggregate cultures of human meniscal cells treated by FGF-2 in the presence of transforming growth factor beta, 20 a factor well known for its metabolic properties in the meniscus. [24] [25] [26] [27] 31, 37 Application of combinations of mitogenic and anabolic factors that also include insulin-like growth factors I and II, 18 platelet-derived growth factor, 19,21-23 bone morphogenic proteins 2 and 7, 22, 23 and hepatocyte growth factor 22 may thus be of additonal value to improve the healing of meniscal lesions. Alternatively, factors such as the vascular endothelial growth factor, 52 hepatocyte growth factor, 22, 33 and platelet-derived growth factor 22 might be considered with FGF-2 53 for their therapeutic effects on cell migration and vasculogenesis. Again, rAAV offer powerful tools to achieve the transfer of multiple candidate genes, as separate vectors can be provided at the same time to their targets under conditions of decreased immune interference. 54 In addition, as regeneration of the treated lesions was not completed despite superior rates of cell proliferation compared with the intact meniscus, it remains to be seen if overexpression of genes in the form delivered here will not alter the integrity of the meniscus over time. Yet, this might be avoided by tight regulation of the transgenes based on the use of regulatable (tetracycline-sensitive) or tissue-specific (type-I collagen) transcriptional elements instead of the strong cytomegalovirus immediate-early promoter. Equally important, such an approach may allow to minimize undesirable transgene expression in the adjacent, healthy tissue by restraining it to cells at the edge of the defect.
In summary, the results of this study indicate that direct application of therapeutic rAAV vectors has the potential to induce beneficial responses in the injured meniscus. Additional studies will be required to test the biomechanical properties of the repair tissue and to evaluate the benefits of the approach in experimental model systems. 14, 34 These findings provide further motivation to develop rAAV-based gene treatments for meniscal lesions in patients.
Materials and methods
Reagents
All reagents were from Sigma (Munich, Germany) except for the dimethylmethylene blue dye (Serva, Heidelberg, Germany) and the collagenase type-I (232 U mg -1 ) (Biochrom, Berlin, Germany). The anti-bromodeoxyuridine (BrdU) (BU 33) and anti-a-SMA (1A4) antibodies were from Sigma, the anti-human FGF-2 (Ab-3) antibody from Oncogene Research Products (Darmstadt, Germany), and the anti-type-I collagen (AF-5610) and anti-type-II collagen (AF-5710) antibodies from Acris Antibodies GmbH (Hiddenhausen, Germany). Quantitative measurements of FGF-2 production were performed using the human FGF basic Quantikine ELISA (DFB50; R&D Systems) with a detection limit of 0.5 pg ml -1 . The type-I collagen and type-II collagen contents were measured with the human type-I collagen and type-II collagen ELISA kits (Chondrex, Redmond, WA, USA).
Meniscus and cells
Human menisci were obtained from knee joints of osteoarthritic patients (ages 50-70 years; n ¼ 12) undergoing total knee arthroplasty. Only menisci without tears or visible degenerative changes on gross examination were used. All patients provided informed consent before inclusion in the study. Meniscal explants and meniscal fibrochondrocytes were prepared as described earlier. 34 Briefly, menisci were washed, diced into 2 Â 2 mm pieces, and transferred to DMEM with 100 U ml -1 penicillin G and 100 mL ml -1 streptomycin (basal medium) with 10% FBS (growth medium) at 37 1C in a humidified atmosphere with 5% CO 2 . Meniscal cells were isolated by adding 0.1% collagenase to the menisci for 16 h. Cells were filtered through a 125-mm mesh to remove the undigested matrix. The cell number was determined by hemocytometry. Viability, as determined by trypan blue exclusion, exceeded 90% in all experiments. The cells were further maintained in growth medium at 37 1C in a humidified atmosphere with 5% CO 2 . A longitudinal lesion (5 mm in length and 0.5 mm in depth) was created with a scalpel in the avascular area Metabolic responses of human meniscal fibrochondrocytes to FGF-2 production M Cucchiarini et al of some intact triangle-shaped meniscal explants (10 mm Â 7 mm, 7 mm in depth) as described earlier 34 and the samples were kept in growth medium at 37 1C in a humidified atmosphere with 5% CO 2 .
The 293 line, an adenovirus-transformed human embryonic kidney cell line was maintained in Eagle's minimal essential medium containing 10% FBS and antibiotics.
Plasmids and rAAV vectors
The constructs used in this study were derived from a parental AAV-2 genomic clone, pSSV9.
55,56 pAd8 contains the AAV-2 replication and encapsidation functions. 56 rAAV-lacZ is an AAV-2-based vector plasmid carrying the lacZ gene encoding b-galactosidase under the control of the cytomegalovirus immediate-early promoter. 43, 44, 47, 57 rAAV-RFP carries a 776-bp Discosoma sp. RFP cDNA fragment that was cloned in rAAV-lacZ instead of the lacZ gene. 43, 57 rAAV-hFGF-2 carries a 480-bp human basic fibroblast growth factor (hFGF-2) cDNA fragment 58 that was cloned in rAAV-lacZ instead of the lacZ gene. 47 rAAV vectors were packaged as conventional (not self-complementary) elements using Adenovirus 5 to provide helper functions in combination with pAd8 and the vector preparations were purified by dialysis and titered by real-time PCR, 43 .
rAAV transduction and cell encapsulation
Monolayer cultures of meniscal fibrochondrocytes (2 Â 10 4 cells) were transduced with rAAV (50 ml each vector) as described earlier 34 and kept in culture for up to 10 days. For three-dimensional cultures, 10 5 cells were transduced (50 ml each vector) and encapsulated in alginate as described earlier. 43, 44, 47 The alginate-cell constructs (spheres) were assessed for cell number and viability at days 0, 5, 9, 14, and 21 post-encapsulation. 43, 44, 47 Single spheres were solubilized, the released cells were counted, and cell viability was assessed using a Neubauer chamber and trypan blue exclusion staining based on four counts per sample.
In situ, the vectors (50 ml each) were directly and homogeneously applied to various zones of the intact entire meniscal explants (peripheral and central parts) or using a Hamilton syringe for injection in the defects. 34 Transduced explants were maintained in culture for up to 15 days.
Gene transfer analyses
Expression of the transgenes was determined either by live fluorescence or by immunocytochemistry and immunohistochemistry using specific primary antibodies, biotinylated secondary antibodies (Vector Laboratories, Alexis Deutschland GmbH, Grü nberg, Germany), 44, 47 and the ABC method (Vector Laboratories) with diaminobenzidine as the chromogen. To control for secondary immunoglobulins, samples were processed with omission of the primary antibody. Samples were either examined directly by fluorescent microscopy using an Olympus microscope with a 568-nm filter (CKX41; Hamburg, Germany) or by light microscopy (Olympus BX 45). Transduction efficiencies were calculated as described earlier. 34 To monitor FGF-2 secretion, transduced samples (primary cell cultures and entire meniscal explants) were washed twice and placed for 24 h in serum-free medium. Supernatants were collected at the denoted time points, centrifuged to remove cell debris, and FGF-2 production was measured by ELISA. 47, 48 Histological evaluations and immunohistochemical analyses Spheres and meniscal explants were histologically processed as described earlier. 43, 44, 47 Paraffin-embedded sections (5 mm) were stained with safranin O to detect proteoglycans with hematoxylin and eosin to detect cells according to routine protocols. 43, 44, 47 Fast green was used as a counterstain. Expression of type-I collagen and type-II collagen was detected by immunohistochemistry using specific antibodies.
Analysis of cell proliferation
The proliferative activities of human meniscal fibrochondrocytes were assessed by immunochemical labeling after BrdU incorporation both in vitro and in situ. Briefly, BrdU was introduced at a final concentration of 3 mg ml -1 in the culture medium of monolayer cultures, alginatecell constructs, and meniscal explants (intact and damaged menisci) 24 h after rAAV transduction using vector doses similar to those applied in the other assays. Samples were then immunochemically processed as described above at the denoted time points to monitor the proliferation rate of cells with a specific anti-BrdU antibody, a biotinylated secondary antibody, and by revelation using the ABC method and diaminobenzidine. Negative controls were performed as described above.
Determination of type-I collagen, type-II collagen, proteoglycan, and DNA contents Spheres were solubilized and the samples (spheres and explants) were digested in papain as described earlier. 43, 44, 47 Type-I collagen and type-II collagen contents were determined by ELISA. The proteoglycan contents were measured by binding to the dimethylmethylene blue dye. 44, 47, 59 The DNA contents were determined with a fluorimetric assay using Hoechst 33258. 24, 27, 44, 47 Measurements were performed using a GENios spectrophotometer/fluorometer (Tecan Deutschland GmbH, Crailsheim, Germany).
Histomorphometric analyses
The intensities of safranin O staining and of type-I and type-II collagen immunostaining, the cell densities, the percents of cells positive for BrdU uptake and for a-SMA expression, and the quantitative assessments of the extent of healing in the meniscal lesions (length, depth, width, three-dimensional area) were measured at 3 standardized sites using 10 serial sections representative of the defect for each parameter and test condition using SIS AnalySIS (Olympus), Adobe Photoshop (Adobe Systems, Unterschleissheim, Germany), and Scion Image (Scion Corporation, Frederick, MD, USA). 9, 11, 60 The percents of safranin O staining intensity were calculated as being the ratio of positively stained tissue surface to the total surface of the site evaluated. Type-I and type-II collagen immunostaining intensities were in pixels per standardized area.
Metabolic responses of human meniscal fibrochondrocytes to FGF-2 production M Cucchiarini et al
Statistical analysis
Data are expressed as mean±standard deviation of separate experiments. Each condition was performed in duplicate in three independent experiments with spheres, meniscal explants, and meniscal lesions. Data were obtained by two individuals that were blinded with respect to the treatment groups. The t-test and the MannWhitney rank sum test were used where appropriate. Any P value of o0.05 was considered statistically significant.
